Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
Midday Glance: Biotechnology companies
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Apr 25, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Will This Analyst Upgrade Help Celgene (CELG) Stock Today?
at The Street - Fri Apr 25, 8:33AM CDT
Piper Jaffray upgraded Celgene (CELG) to "overweight" from "neutral" and set a $170 price target. The firm cited valuation, as the stock has lagged over the past couple of months.
Celgene Corporation to Present at Investor Conferences in May
Business Wire - Fri Apr 25, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at four upcoming investor conferences in the month of May. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.
Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Fri Apr 25, 6:59AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $141.25 on volume of 4.4 million shares, above average daily volume of 4.3 million. Potential upside of 37.1% exists for Celgene, based on a current level of $141.25 and analysts' average consensus price target of $193.60. Celgene shares should first meet resistance at the 50-day moving average (MA) of $150.91 and find additional resistance at the 200-day MA of $152.22.
'Mad Money' Lightning Round: United Rentals Is Really Good
at The Street - Fri Apr 25, 5:00AM CDT
Cramer prefers HollyFrontier to CVR Refining and says wait a bit on GW Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Nerds Rule
at The Street - Thu Apr 24, 7:19PM CDT
Uncool companies left for dead last quarter are making a comeback, Cramer says.
Final Glance: Biotechnology companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Caterpillar and D.R. Horton are big market movers
AP - Thu Apr 24, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:27PM CDT
Product sales increased at Celgene (CELG) in the quarter.
Oncology Drug Growth Fuels Celgene's Q1 Profit Higher by 22%
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 24, 11:21AM CDT
Cancer-focused biopharmaceutical behemoth Celgene today reported steady growth in many of its key products and a higher adjusted profit in the first quarter despite a clear-cut rise in expenses. For the quarter, Celgene delivered total revenue...
June 6th Options Now Available For Celgene (CELG)
at The Street - Thu Apr 24, 11:14AM CDT
Investors in Celgene Corp. saw new options begin trading today, for the June 6th expiration.
Jim Cramer Breaks Down Apple (AAPL), Caterpillar (CAT) and American Airlines Group's (AAL) Earnings
at The Street - Thu Apr 24, 11:04AM CDT
TheStreet's Jim Cramer breaks down Apple (AAPL), Caterpillar (CAT) and American Airlines Group's (AAL) earnings.
Alexion, Celgene Report Contrasting Q1 Earnings
at Investor's Business Daily - Thu Apr 24, 10:39AM CDT
Big-cap biotech Alexion Pharmaceuticals (ALXN) beat Q1 estimates and raised its full-year-earnings guidance Thursday, sending the stock up 3% in morning trading on the stock market. Fellow biotech giant Celgene (CELG) missed, however. Alexion...
Jim Cramer's Stop Trading: CELG
at The Street - Thu Apr 24, 10:06AM CDT
Celgene is a very cheap stock but investors aren't willing to buy it, Cramer says.